One capsule contains
- Active Ingredients: Piracetam 400mg, Cinnarizine 25mg,
- Excipients: lactose monohydrate, colloidal silicon dioxide, magnesium stearate,
- The composition of the capsule shell: titanium dioxide (E 171), gelatin.
Rapidly and completely absorbed from the gastrointestinal tract. The maximum concentration of cinnarizine in plasma is noted after 1-4 hours, piracetam – after 2-6 hours.
A high concentration of cinnarizine after 1-4 hours is noted in the liver, kidneys, heart, lungs, spleen and brain. Cinnarizine is 91% bound to plasma proteins. Piracetam is rapidly distributed to all vital organs. It penetrates the blood-brain barrier and is concentrated mainly in the gray matter of the cerebral cortex and cerebellum, as well as in the nucleus caudatus (caudate nucleus), hippocampus (hippocampus), corpus medianum, geniculus lateralis and plexus choroidalis (choroidal plexus).
Piracetam is excreted unchanged in the urine in about 30 hours. 60% of cinnarizine is excreted unchanged in the feces, the rest is excreted in the urine as metabolites in about 5 hours.
Combined drug that improves cerebral circulation and brain metabolism.
Piracetam is a nootropic. It has a positive effect on metabolic processes and blood circulation in the brain. Increases the utilization of glucose, improves the course of metabolic processes, improves microcirculation in ischemic areas, inhibits the aggregation of activated platelets. It has a protective effect in case of brain damage caused by hypoxia.
Cinnarizine is a calcium channel blocker with a pronounced effect on the vessels of the brain, reduces the entry of Ca2 + into cells and reduces its content in the plasma membrane depot, reduces the tone of the smooth muscles of arterioles, and reduces their response to biogenic vasoconstrictor substances. It has a vasodilating effect, without significantly affecting blood pressure. Improves cerebral circulation, increases the resistance of tissues to hypoxia. Reduces the excitability of the vestibular apparatus.
Both components mutually potentiate each other’s action. With regard to the effect of the drug on the central nervous system, the sedative effect of cinnarizine prevails. The toxicity of the combination does not exceed the toxicity of the individual components. The therapeutic effect appears after 1-6 hours.
Indications for use
– violations of cerebral circulation: with atherosclerosis of cerebral vessels,
– recovery period after ischemic and hemorrhagic strokes, after craniocerebral injuries
– psychoorganic syndrome with a predominance of memory impairment and other cognitive functions or disorders of the emotional-volitional sphere
– encephalopathy of various origins
– labyrinthopathy of various origins (dizziness, tinnitus, nausea, vomiting, nystagmus)
– Meniere’s syndrome
– prevention of kinetosis and migraine
– to improve the learning and memory of children with intellectual retardation.
Dosage and administration
For adults, the drug is prescribed 1-2 capsules three times a day for 1-3 months, depending on the severity of the disease.
Children from 6 years of age are prescribed 1-2 capsules 1-2 times a day.
The drug should not be taken for more than 3 months!
It is advisable not to skip taking Phezam®, especially if it is prescribed once. If this occurs, the capsule should be taken immediately, but if the next dose is due, the missed dose should not be taken.
The overall frequency of adverse events is comparable to that of placebo.
The frequency of occurrence of adverse reactions is estimated as follows: “very often” 1/10, “often” – from 1/100 to <1/10, “sometimes” – from 1/1000 to <1/100, “rarely ” – from > 1/10000 to < 1/1000, “very rarely” – < 1/10000.
– rash, itching, photosensitivity
– epigastric pain, dyspepsia, nausea, vomiting
– headache, dry mouth, irritability
– tremor of the limbs, increased muscle tone.
– hypersensitivity to the components of the drug
– severe renal and / or liver failure
– lactation period
– children under 6 years old
– hemorrhagic stroke
When taken simultaneously with Phezam®, it is possible to enhance the effect of hypnotics and sedatives, tricyclic antidepressants, nootropic and antihypertensive drugs, as well as ethanol. Combined use with vasodilators enhances its effect, and the presence of cinnarizine leads to a decrease in the activity of hypertensive drugs.
The drug increases the activity of thyroid hormones and can cause tremors and restlessness. May also enhance the effect of oral anticoagulants.
Caution should be used in conditions associated with increased intraocular pressure or in patients with Parkinson’s disease. The drug should be used with caution in persons with liver and / or kidney disease. In cases of mild to moderate renal insufficiency (especially if creatinine clearance is less than 60 ml / min), the therapeutic dose should be reduced or the intervals between doses should be increased.
In persons with impaired liver function, monitoring of the content of liver enzymes is necessary.
Alcohol should be avoided during treatment.
The drug can cause a false positive reaction in the control of doping drugs in athletes.
Features of influence on the ability to drive a vehicle or potentially dangerous mechanisms
There is no data on the effect of the drug on the ability to drive a car and work with machinery.
Symptoms are abdominal pain. In children, excitation reactions predominate: insomnia, irritability, tremors, in rare cases, nightmares, hallucinations, convulsions.
Treatment is symptomatic.
Phezam® is very well tolerated by patients; in case of an overdose, there are no serious side effects requiring discontinuation of the drug.
Store in a dry, dark place at a temperature not exceeding 25°C.
Keep out of the reach of children!
Shelf life – 3 years
The drug should not be used after the expiration date indicated on the package.